New hope for Tough-to-Treat leukemia
NCT ID NCT05289687
Summary
This study is testing a drug called daratumumab-hyaluronidase for adults with T-cell acute lymphoblastic leukemia (T-ALL) who have a small amount of cancer cells left after chemotherapy. The goal is to see if this drug can eliminate these remaining cells and prevent the cancer from returning. Researchers will measure if patients achieve a 'complete response' and monitor their survival and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.